Lung Non-Small Cell Carcinoma

In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC)

PMID 22056021 · Pirker et al., 2012 · Open in CIViC

In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC)

PMID 26439803 · Park et al., 2015 · Open in CIViC

In transduced cos7 cells, P772_H773insH cells showed increased sensitivity to erlotinib in comparison to cells with T790M resistance mutation, but decreased erlotinib sensitivity in comparison to L858… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best respon… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 57 year old male 10 packyear former smoker with lung adenocarcinoma with EGFR P772_V774insPHV mutation was given erlotinib as first line treatment, and had progressive disease as best response with … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR P848L demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

A metastatic lung adenocarcinoma (bone and brain) was diagnosed in a 42-year-old woman (patient 3). The primary adenocarcinoma was found in left lower lobe (LLL). Her initial treatment with whole-brai… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generati… (full text at CIViC)

PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. Ligand binding causes receptor homo- or hetero-dimerization, leading to acti… (full text at CIViC)

PMID 20966921 · Pao et al., 2010 · Open in CIViC

EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4.

PMID 15870435 · Cappuzzo et al., 2005 · Open in CIViC

In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized. One Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibito… (full text at CIViC)

PMID 23344264 · Yeh et al., 2013 · Open in CIViC

106 Chinese patients who received second-line gefitinib were screened for EGFR mutations. One Patient with an EGFR R832L Mutation achieved stable disease. Treatment was ongoing after 7 months at the t… (full text at CIViC)

PMID 19020901 · Xu et al., 2009 · Open in CIViC

A 62 year-old female never smoker diagnosed of lung adenocarcinoma that was negative for EGFR and ALK alterations (EGFR hotspot tissue NGS) was treated with carboplatin/ pemetrexed/ bevacizumab (x 6 c… (full text at CIViC)

PMID 29472054 · Raez et al., 2018 · Open in CIViC

A 48 year old male with lung adenocarcinoma who was a smoker presented with diminished vision and tinnitus, and multiple intracranial brain metastasis were identified by CT. Metastatic site was submit… (full text at CIViC)

PMID 29290255 · Zhu et al., 2018 · Open in CIViC

Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mut… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had p… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor su… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR S768_D770insSVD mutation was associated with resistance to erlotinib treatment. The patient su… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, two patients with the EGFR exon 20 insertion S768_D770dup received osimertinib treatment. A 59 year old f… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor sam… (full text at CIViC)

PMID 25521405 · Hellmann et al., 2014 · Open in CIViC

S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treate… (full text at CIViC)

PMID 27211795 · Leventakos et al., 2016 · Open in CIViC

In a phase 2 trial, 129 patients with lung adenocarcinoma with EGFR mutations including mutations other than exon 19 deletions or exon 21 L858R substitutions who had no more than one previous chemothe… (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC